Mavupharma is focused on approaches to target the STING (STimulator of INterferon Genes) pathway for the treatment of cancer.
"AbbVie's vision in oncology is to advance breakthrough areas of science leading to a strong pipeline of innovative cancer therapies," said Steve Davidsen, AbbVie's vice president of oncology discovery. "Mavupharma's platform has the potential to further our immuno-oncology portfolio and assist in the development of transformative medicines for patients."
AbbVie shares are around $70.28 on Monday. The stock has a 52-week high of $100.23 and a 52-week low of $65.06.
AbbVie To Acquire Allergan In B Deal
Callon Petroleum To Acquire Carrizo In All Stock Deal
See more from Benzinga
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.